336 related articles for article (PubMed ID: 15598967)
21. Monotherapy with meropenem versus combination therapy with piperacillin plus amikacin as empiric therapy for neutropenic fever in children with lymphoma and solid tumors.
Düzova A; Kutluk T; Kanra G; Büyükpamukçu M; Akyüz C; Seçmeer G; Ceyhan M
Turk J Pediatr; 2001; 43(2):105-9. PubMed ID: 11432485
[TBL] [Abstract][Full Text] [Related]
22. Meropenem in the treatment of febrile neutropenic children.
Müller J; Garami M; Constantin T; Schmidt M; Fekete G; Kovács G
Pediatr Hematol Oncol; 2005 Jun; 22(4):277-84. PubMed ID: 16020114
[TBL] [Abstract][Full Text] [Related]
23. Population pharmacokinetic analysis of meropenem in Japanese adult patients.
Muro T; Sasaki T; Hosaka N; Umeda Y; Takemoto S; Yamamoto H; Kamimura H; Higuchi S; Karube Y
J Clin Pharm Ther; 2011 Apr; 36(2):230-6. PubMed ID: 21366653
[TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetics and pharmacodynamics of meropenem in elderly chinese with lower respiratory tract infections: population pharmacokinetics analysis using nonlinear mixed-effects modelling and clinical pharmacodynamics study.
Zhou QT; He B; Zhang C; Zhai SD; Liu ZY; Zhang J
Drugs Aging; 2011 Nov; 28(11):903-12. PubMed ID: 22054231
[TBL] [Abstract][Full Text] [Related]
25. Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution.
Roberts JA; Kirkpatrick CM; Roberts MS; Robertson TA; Dalley AJ; Lipman J
J Antimicrob Chemother; 2009 Jul; 64(1):142-50. PubMed ID: 19398460
[TBL] [Abstract][Full Text] [Related]
26. Meropenem pharmacokinetics, pharmacodynamics, and Monte Carlo simulation in the neonate.
Bradley JS; Sauberan JB; Ambrose PG; Bhavnani SM; Rasmussen MR; Capparelli EV
Pediatr Infect Dis J; 2008 Sep; 27(9):794-9. PubMed ID: 18645546
[TBL] [Abstract][Full Text] [Related]
27. Suboptimal aminoglycoside dosing in critically ill patients.
Rea RS; Capitano B; Bies R; Bigos KL; Smith R; Lee H
Ther Drug Monit; 2008 Dec; 30(6):674-81. PubMed ID: 19057371
[TBL] [Abstract][Full Text] [Related]
28. Clinical pharmacokinetics of meropenem in pancreatic juice and site-specific pharmacodynamic target attainment against Gram-negative bacteria: dosing considerations.
Kondo N; Ikawa K; Murakami Y; Uemura K; Sudo T; Hashimoto Y; Ohge H; Morikawa N; Sueda T
Pancreatology; 2014; 14(2):95-9. PubMed ID: 24650961
[TBL] [Abstract][Full Text] [Related]
29. Comparative pharmacokinetics and pharmacodynamics of doripenem and meropenem in obese patients.
Kays MB; Fleming MR; Cheatham SC; Chung EK; Juenke JM
Ann Pharmacother; 2014 Feb; 48(2):178-86. PubMed ID: 24259653
[TBL] [Abstract][Full Text] [Related]
30. Treatment and outcome of Pseudomonas aeruginosa bacteraemia: an antibiotic pharmacodynamic analysis.
Zelenitsky SA; Harding GK; Sun S; Ubhi K; Ariano RE
J Antimicrob Chemother; 2003 Oct; 52(4):668-74. PubMed ID: 12951354
[TBL] [Abstract][Full Text] [Related]
31. Meropenem by continuous versus intermittent infusion in ventilator-associated pneumonia due to gram-negative bacilli.
Lorente L; Lorenzo L; Martín MM; Jiménez A; Mora ML
Ann Pharmacother; 2006 Feb; 40(2):219-23. PubMed ID: 16449546
[TBL] [Abstract][Full Text] [Related]
32. Treatment of Serratia marcescens meningitis with prolonged infusion of meropenem.
Nicasio AM; Quintiliani R; DeRyke CA; Kuti JL; Nicolau DP
Ann Pharmacother; 2007 Jun; 41(6):1077-81. PubMed ID: 17472997
[TBL] [Abstract][Full Text] [Related]
33. Clinical outcomes and cost minimization with an alternative dosing regimen for meropenem in a community hospital.
Patel GW; Duquaine SM; McKinnon PS
Pharmacotherapy; 2007 Dec; 27(12):1637-43. PubMed ID: 18041884
[TBL] [Abstract][Full Text] [Related]
34. Applying the Multinational Association for Supportive Care in Cancer risk scoring in predicting outcome of febrile neutropenia patients in a cohort of patients.
Baskaran ND; Gan GG; Adeeba K
Ann Hematol; 2008 Jul; 87(7):563-9. PubMed ID: 18437382
[TBL] [Abstract][Full Text] [Related]
35. Empiric monotherapy in neutropenia: a realistic goal?
Del Favero A; Bucaneve G; Menichetti F
Scand J Infect Dis Suppl; 1995; 96():34-7. PubMed ID: 7652501
[TBL] [Abstract][Full Text] [Related]
36. Clinical guidelines for the management of neutropenic patients with unexplained fever in Japan: validation by the Japan Febrile Neutropenia Study Group.
Tamura K
Int J Antimicrob Agents; 2005 Dec; 26 Suppl 2():S123-7; discussion S133-40. PubMed ID: 16249072
[TBL] [Abstract][Full Text] [Related]
37. Role of renal function in risk assessment of target non-attainment after standard dosing of meropenem in critically ill patients: a prospective observational study.
Ehmann L; Zoller M; Minichmayr IK; Scharf C; Maier B; Schmitt MV; Hartung N; Huisinga W; Vogeser M; Frey L; Zander J; Kloft C
Crit Care; 2017 Oct; 21(1):263. PubMed ID: 29058601
[TBL] [Abstract][Full Text] [Related]
38. Bioequivalence, antibacterial activity and therapeutic outcome of a generic meropenem (Mapenem).
Leelarasamee A; Rongrungruang Y; Trakulsomboon S; Pongpech P; Thanawattanawanich P; Jithavech P
J Med Assoc Thai; 2008 Jul; 91(7):980-8. PubMed ID: 18839835
[TBL] [Abstract][Full Text] [Related]
39. Pharmacokinetic-pharmacodynamic rationale for cefepime dosing regimens in intensive care units.
Roos JF; Bulitta J; Lipman J; Kirkpatrick CM
J Antimicrob Chemother; 2006 Nov; 58(5):987-93. PubMed ID: 16943209
[TBL] [Abstract][Full Text] [Related]
40. Pharmacokinetics/pharmacodynamics of antofloxacin hydrochloride in a neutropenic murine thigh model of Staphylococcus aureus infection.
Xiao XM; Xiao YH
Acta Pharmacol Sin; 2008 Oct; 29(10):1253-60. PubMed ID: 18817632
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
